An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
BeiGene (NASDAQ: BGNE) announced its participation in the J.P. Morgan 41st Annual Healthcare Conference, scheduled for January 9, 2023, at 1:30 p.m. PT. A live webcast will be available on the investors section of BeiGene's website, with an archived replay accessible for 90 days post-event. The company is a global biotechnology firm focused on developing innovative oncology treatments to improve accessibility and outcomes for patients worldwide. With over 9,000 employees globally, BeiGene aims to enhance treatment access for numerous patients.
Positive
None.
Negative
None.
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology companytoday announced that the Company will participate in the J.P. Morgan 41st Annual Healthcare Conferenceon Monday, January 9, 2023 at 1:30 p.m. PT.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Cambridge, U.S., & Basel, Switzerland & Beijing, China. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.
When will BeiGene participate in the J.P. Morgan Healthcare Conference?
BeiGene will participate in the J.P. Morgan 41st Annual Healthcare Conference on January 9, 2023, at 1:30 p.m. PT.
How can I access BeiGene's webcast for the healthcare conference?
The live webcast for BeiGene's participation in the healthcare conference can be accessed through the investors section of their website at ir.beigene.com.
What is BeiGene's focus in biotechnology?
BeiGene focuses on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide.
How long will the archived replay of BeiGene's conference be available?
An archived replay of BeiGene's conference will be available for 90 days following the event.
